The FDA, in reviewing the guidelines that cover the lifetime ban on men who have sex with men from donating blood, should focus only on whether a change to the policy would make the blood supply more vulnerable to transfusion-related illnesses, according to this Los Angeles Times editorial. If the FDA decides to change the policy, it should mandate reporting of whether the amended policy leads to more donated blood testing positive for diseases, the editorial board writes.

Related Summaries